Seratrodast
Seratrodast is an inhibitor of the thromboxane A2 receptor and exhibits anti-asthma and anti-inflammatory activity but no anti-platelet benefits. Seratrodast is used clinically to treat asthma, preventing bronchial hyperresponsiveness and bronchoconstriction as well as improving cough threshold.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18971922
| Cas No. |
112665-43-7 |
|---|---|
| Purity |
≥98% |
| Formula |
C22H26O4 |
| Formula Wt. |
354.44 |
| IUPAC Name |
7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoicacid |
| Melting Point |
128-129°C |
| Appearance |
Yellow powder |
An J, Li JQ, Wang T, et al. Blocking of thromboxane A2 receptor attenuates airway mucus hyperproduction induced by cigarette smoke. Eur J Pharmacol. 2013 Mar 5;703(1-3):11-7. PMID: 23399768.
Dogné JM, de Leval X, Benoit P, et al. Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med. 2002;1(1):11-7. PMID: 14720071.
Ishiura Y, Fujimura M, Yamamori C, et al. Thromboxane antagonism and cough in chronic bronchitis. Ann Med. 2003;35(2):135-9. PMID: 12795341.
